Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease

The studies span investigational and commercial CAR T-cell therapies and donor stem cell transplantation for severe sickle cell disease.

Rhea-AI Summary

Actinium Pharmaceuticals (ATNM) announced three ASH abstracts covering Iomab-ACT clinical findings and development before cellular therapies for cancer and severe sickle cell disease. Iomab-ACT is an investigational targeted radiation treatment used for conditioning, which prepares patients for cellular therapy.

A Memorial Sloan Kettering Cancer Center study evaluated conditioning before investigational CD19-directed CAR T-cell therapy, focusing on immune cell depletion, CAR T-cell expansion and treatment-related toxicities. A separate Phase 1b/2 study evaluates conditioning before standard commercial CD19-directed CAR T-cell therapy. The sickle cell disease abstract presents preliminary results of conditioning before stem cell transplantation from an HLA-matched sibling donor. Actinium aims to develop the approach across cellular and gene therapies while reducing reliance on conventional chemotherapy.

Positive

• Minor pointMemorial Sloan Kettering study reports immune cell depletion without severe CRS or neurologic toxicity before investigational CAR T-cell therapy.
• Minor pointPhase 1b/2 study evaluates Iomab-ACT conditioning before standard commercial CD19-directed CAR T-cell therapy.
• Minor pointSevere sickle cell disease clinical experience evaluates conditioning to support donor engraftment without conventional chemotherapy.

Negative

• Minor pointSickle cell disease conditioning results remain preliminary.

Key Figures

Abstracts: 3 abstracts Study phase: Phase 1b/2

Abstracts

3 abstracts

ASH 2026 abstract announcement

Study phase

Phase 1b/2

Iomab-ACT before standard commercial CD19-directed CAR T-cell therapy

Key Terms

car t-cell therapy, allogeneic stem cell transplantation, radioimmunotherapy, nonmyeloablative conditioning, +1 more

5 terms

car t-cell therapy medical

"conditioning before CAR T-cell therapy and allogeneic stem cell transplantation"

Car T-cell therapy is a medical treatment that uses a patient’s own immune cells, modified in a lab to better recognize and attack cancer cells. It is considered a breakthrough because it offers potentially long-lasting effects for certain types of cancer. For investors, its development and approval can signal advances in healthcare innovation and potential growth opportunities in the biotech sector.

allogeneic stem cell transplantation medical

"before CAR T-cell therapy and allogeneic stem cell transplantation for severe sickle cell disease"

A procedure in which a patient receives blood-forming (hematopoietic) stem cells from a donor rather than from their own body; the donated cells (from a related or unrelated matched donor, cord blood, or a haploidentical donor) are infused after the recipient undergoes conditioning therapy to eradicate diseased marrow and suppress the immune system. It is used to restore normal blood and immune-cell production for diseases such as leukemia, lymphoma, certain genetic blood disorders, and some immune deficiencies; because the graft is genetically non‑identical to the recipient, the transplant requires ongoing immune suppression and carries risks such as graft‑versus‑host disease and graft failure.

radioimmunotherapy medical

"investigational CD45-targeted radioimmunotherapy"

A cancer treatment that uses disease‑targeting antibodies as delivery vehicles to carry small doses of radiation directly to tumor cells, like a smart missile that seeks the enemy while sparing nearby healthy tissue. Investors care because successful radioimmunotherapy can become a high‑value drug class with clear clinical and regulatory milestones, affecting a company’s sales potential, trial risk profile, and valuation as it moves through testing and approval.

nonmyeloablative conditioning medical

"as Nonmyeloablative Conditioning for HLA-Matched Sibling Allogeneic Stem Cell Transplantation"

A chemotherapy and/or radiation regimen given before a hematopoietic (bone marrow or stem cell) transplant that does not fully destroy the recipient’s bone marrow or immune system but suppresses it enough to allow donor stem cell engraftment. Nonmyeloablative conditioning is designed to reduce short‑term toxicity compared with full myeloablation and typically relies on sustained immune suppression and the donor immune system’s activity (graft‑versus‑disease effects) to control the underlying disorder; it therefore may not eradicate disease as thoroughly up front and still carries risks such as infection and graft‑versus‑host disease.

lymphodepletion medical

"serves as a promising means of lymphodepletion while preventing severe CRS"

Lymphodepletion is a short medical treatment that lowers a patient’s lymphocytes, the immune cells that can interfere with certain cell-based therapies, to create a more supportive environment for the new therapy to work. Think of it like clearing a crowded garden bed before planting seeds: by temporarily reducing competing cells, the engineered therapy can take hold more effectively. Investors watch lymphodepletion because it affects clinical trial results, safety profiles, treatment adoption, and overall commercial potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• The three abstracts strengthen the clinical foundation for Iomab-ACT's development as a targeted conditioning platform for cellular and gene therapies across cancer and nonmalignant diseases
• Phase 1b/2 trial evaluates targeted immune conditioning with Iomab-ACT before standard commercial CD19-directed CAR T-cell therapy
• Memorial Sloan Kettering Cancer Center study demonstrates promise of Iomab-ACT as targeted conditioning agent before CAR T-cell therapy, with a focus on CAR T-cell expansion, immune cell depletion and treatment-related toxicities
• Clinical experience in severe sickle cell disease evaluates Iomab-ACT-based conditioning to support donor engraftment without conventional chemotherapy

NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced the release of three abstracts for the 68th American Society of Hematology (ASH) Annual Meeting and Exposition. The abstracts highlight clinical findings and continued development of Iomab-ACT, the Company's investigational CD45-targeted radioimmunotherapy, as a conditioning approach before CAR T-cell therapy and allogeneic stem cell transplantation for severe sickle cell disease.

The abstracts include results from the Memorial Sloan Kettering Cancer Center study of Iomab-ACT before investigational CD19-directed CAR T-cell therapy, preliminary results from the Iomab-ACT-based conditioning regimen for severe sickle cell disease, and a Phase 1b/2 study evaluating Iomab-ACT before standard commercial CD19-directed CAR T-cell therapy. Together, these studies explore the potential of targeted radiation to prepare patients for cellular therapies while reducing reliance on conventional chemotherapy conditioning.

Sandesh Seth, Actinium's Chairman and CEO, stated, "These ASH presentations mark an important step in the development of our Iomab-ACT CD45-targeted radiotherapy conditioning program. Iomab-ACT is a highly differentiated conditioning agent designed to prepare patients for cellular and gene therapies through targeted radiation rather than conventional chemotherapy. Building on the promising initial clinical experience with investigational CD19-directed CAR T-cell therapy, we are excited by the opportunity to evaluate Iomab-ACT with commercial CAR T-cell therapies. The clinical experience in severe sickle cell disease further highlights its potential beyond cancer. Together, these studies support our goal of establishing Iomab-ACT as a universal targeted conditioning regimen for cellular and gene therapies."

Iomab-ACT ASH 2026 Presentation Details

Abstract Title: First Preliminary Results of Anti-CD45 ¹³¹I-Radioimmunotherapy (Iomab-ACT) as Nonmyeloablative Conditioning for HLA-Matched Sibling Allogeneic Stem Cell Transplantation in Severe Sickle Cell Disease (SCD)
Session Title: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II
Presenting Author: Markus Y. Mapara, Columbia University Irving Medical Center
Location: Ernest N. Morial Convention Center, Hall F
Date: Sunday, December 13, 2026
Time: 6:00 PM – 8:00 PM

Abstract Title: Low-dose ¹³¹I apamistamab prior to adoptive cellular therapy (Iomab-ACT) for relapsed/refractory DLBCL and B-cell ALL serves as a promising means of lymphodepletion while preventing severe CRS and neurologic toxicity
Lead Author: Mark Geyer, Memorial Sloan Kettering Cancer Center

Abstract Title: Precision CD45-directed ¹³¹I radioimmunotherapy immune conditioning before CD19-directed CAR T-cell therapy for lymphoid malignancies: the phase 1b/2 IOMAB-ACT trial
Lead Author: Farrukh T. Awan, UT Southwestern Medical Center

About Iomab-ACT

Iomab-ACT is an investigational CD45-targeted antibody radioconjugate combining apamistamab with iodine-131. It is being studied as a targeted conditioning approach before cellular therapies, including CAR T-cell therapy and allogeneic stem cell transplantation. By delivering radiation to CD45-expressing hematopoietic and immune cells, Iomab-ACT is designed to prepare the host immune environment for subsequent cellular therapy. Its safety and efficacy remain under clinical investigation.

About Actinium Pharmaceuticals, Inc.

Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry. Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial, with additional development ongoing through a CRADA with the NCI. Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225. For more information, please visit www.actiniumpharma.com.

Forward-Looking Statements

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Investor Contact

Peter (PJ) Kelleher
LifeSci Advisors
pkelleher@lifesciadvisors.com
(617) 430-7579

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-three-ash-2026-abstracts-highlighting-iomab-act-clinical-results-in-car-t-cell-therapy-and-sickle-cell-disease-302929345.html

SOURCE Actinium Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Actinium's Phase 1b/2 Iomab-ACT trial evaluate?

The Phase 1b/2 IOMAB-ACT trial evaluates targeted immune conditioning before standard commercial CD19-directed CAR T-cell therapy for lymphoid malignancies. Conditioning prepares patients to receive cellular therapy.

What are the Iomab-ACT sickle cell disease findings presented at ASH 2026?

The abstract presents first preliminary results of Iomab-ACT-based conditioning before stem cell transplantation from an HLA-matched sibling donor in severe sickle cell disease. The clinical experience evaluates conditioning to support donor engraftment without conventional chemotherapy.